Celavie Biosciences, LLC has completed four year follow-up in the First-in-Human Exploratory Clinical Safety Study in seven patients with Parkinson’s Disease (see Clinical Trial). This study utilizing our human allogeneic pluripotent stem cells has demonstrated absence of stem cell related adverse events (no tumor formation, no infection and no immune rejection as well as safety of the used stereotactic technique (no surgical complications).
Based on the results of this study, Celavie Biosciences is applying to FDA for the Phase I double blind, placebo controlled, randomized clinical trial in patients with moderate to advanced PD.
Welcome to Celavie Biosciences, where we are improving lives and restoring hope by changing the paradigm of stem cell technology.
At Celavet, a subsidiary, we are applying the same proprietary technologies for the treatment and prevention of serious veterinary diseases. Offering a faster path to market, Celavet Stem Cells have demonstrated safety and restored functions in orthopedic conditions in large and small animals.